베루 (VERU) 주가

베루(VERU)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.73 (+1.11%), 시가총액 $0.03B, 52주 범위 $0.37 ~ $4.43.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microt

핵심 지표

• 현재가: $2.73 (+1.11%)
• 시가총액: $0.03B
• 52주 최저~최고: $0.37 ~ $4.43
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

베루의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

베루 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.2

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.98
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문